Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
David R. Barnidge, Ph.D., is a mass spectrometrist specializing in the development of new ways to analyze antibodies, also called immunoglobulins. Dr. Barnidge and pathologist David L. Murray, M.D., Ph.D., invented a new methodology called monoclonal immunoglobulin Rapid Accurate Molecular Mass (miRAMM), used to diagnose patients with B cell disorders by using mass spectrometry to measure the molecular weight of the antibodies secreted by B cells. This technology provides clinicians with an individualized picture of each patient's immune system, allowing them to treat patients more effectively.
Dr. Barnidge is currently using mass spectrometry to measure therapeutic mAbs in clinical trials. He is also using the methodology to help in the interpretation of difficult cases where current methods have provided inconclusive results. Dr. Barnidge is actively translating his findings to both research laboratories and clinical chemistry laboratories to advance the understanding of the immune system and to improve patient care.
Learn about clinical trials that address specific scientific questions about human health and disease.
Explore all research studies at Mayo Clinic.
See the peer-reviewed findings I have published as a result of my research.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.